E-ISSN: 2791-8823
COVID-19 in Special Patient Groups [Cam Sakura Med J]
Cam Sakura Med J. 2023; 3(2): 39-45 | DOI: 10.4274/csmedj.galenos.2022.2022-11-3

COVID-19 in Special Patient Groups

Ayşegül İnci Sezen, Zuhal Yeşilbağ, Hayat Kumbasar Karaosmanoğlu
University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, İstanbul, Turkey

At the end of 2019, a new coronavirus was identified as the cause of many pneumonia cases in Wuhan, a city in China’s Hubei Province. These cases spread rapidly, causing an epidemic throughout China, followed by increasing cases in other countries. In February 2020, the World Health Organization defined the definition of Coronavirus disease-2019 (COVID-19), which means 2019 coronavirus disease. The virus that causes COVID-19 is called severe acute respiratory syndrome-coronavirus-2. The rapidly expanding COVID-19 pandemic has affected all areas of daily life, including medical care. Although this epidemic significantly affected individuals from all parts of society, the clinical course, diagnosis, and treatment approaches may differ in some specific populations. The association of COVID-19 with various medical comorbidities and its impact on specific and vulnerable populations need to be addressed separately. This information will also assist in the management of COVID-19. The effects and the relationship of COVID-19 on comorbidities (chronic renal, diabetes mellitus, chronic liver, etc.) and special populations (pregnant, elderly, transplant patients, etc.) are comprehensively presented in the text.

Keywords: Chronic disease, comorbidity, COVID-19, special populations

Ayşegül İnci Sezen, Zuhal Yeşilbağ, Hayat Kumbasar Karaosmanoğlu. COVID-19 in Special Patient Groups. Cam Sakura Med J. 2023; 3(2): 39-45

Corresponding Author: Hayat Kumbasar Karaosmanoğlu, Türkiye
Manuscript Language: English
LookUs & Online Makale